Martin Auster joins Ascendis Pharma as Chief Business Officer

The company uses its TransCon technology to create drugs that address unmet medical needs

Ascendis Pharma, a biotechnology company that applies its TransCon technology to develop a pipeline of therapeutics to address unmet medical needs, has appointed Martin Auster as Chief Business Officer.

Auster joins the company, which is headquartered in Palo Alto, CA, US and in Hellerup, Denmark, from United Therapeutics, where he was Vice President, Business Development.

Prior to United Therapeutics, Auster worked in the investment banking industry, including as a Senior Biotechnology Analyst at Wachovia Securities and a Senior Analyst/Healthcare-focused Portfolio Manager at GLG Partners.

You may also like

Research & Development

Amolyt receives FDA fast track designation for hypoparathyroidism drug

The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Marketing

Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation

The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Research & Development

OGT launches new SureSeq myeloid fusion panel drive myeloid cancer research

The assay enables users to integrate research techniques with a single, streamlined NGS process, expediting the process
Regulatory

Tivdak receives US FDA approval for treating recurrent cervical cancer

The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Manufacturing

Marchesini Group at Achema 2024: celebrating 50 years of innovation

At G3, Hall 3.1, the Marchesini Group will exhibit pharmaceutical manufacturing machines, packaging solutions and digital tools to enhance manufacturing processes
Regulatory

Compact process thermostat for efficient temperature control in the lab

The Petite Fleur allows for laboratory reactor temperature control between -40 °C to +200 °C with a 480W refrigeration capacity
Research & Development

Lonza's AI-enabled small molecule development tool launches

The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Subscribe now